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Introduction
Metronidazole is commonly used to treat intra-abdominal infections in neonates.1,2 The
parent drug is converted to 5 metabolites, with 2-hydroxy-metronidazole being the most
clinically significant, as it possesses 30–65% of the antimicrobial activity of the parent
compound.3,4 In vitro studies have demonstrated that cytochrome P450 2A6 (CYP2A6) is
the primary catalyst responsible for metronidazole hydroxylation.5 This enzyme is initially
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expressed at low levels at birth, with expression increasing over the course of the first year
of life to reach adult levels.6 CYP2A6 is known to be a highly polymorphic gene with more
than 45 variant alleles that result in inactive to ultra-rapid metabolizer phenotypes.
Additionally, certain allelic variants such as CYP2A6*17 have amino acid changes that alter
metabolism for some but not other substrates, resulting in different metabolizing phenotypes
for the same genotype.7 The role of genetic variation on variable metronidazole metabolism
in neonates has not been previously described, nor has the effect of CYP2A6*17 on
metronidazole been characterized. As such, the objective of this study was to evaluate the
effect of CYP2A6 genetic variation on the pharmacokinetics of metronidazole in a small
cohort of preterm neonates.

Methods
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This multicenter study was approved by the institutional review boards at each center, and
informed consent was obtained from a parent or guardian of each infant prior to enrollment
and included permission for genetic analysis. A detailed description of the study design as
well as the pharmacokinetic (PK) analysis from the study have been published.8 Briefly,
genetic samples for a cohort of 14 neonates were obtained from the leftover cellular
components of plasma PK samples from a larger cohort of 24 preterm neonates. Infants were
≤32 weeks gestational age (GA) at birth and <91 days postnatal age (PNA), and required
medical treatment with intravenous metronidazole as indicated by microbiological cultures
or clinical signs concerning for infection. Metronidazole was administered as a median
(range) loading dose of 15.0 mg/kg (13.6–19.0) over 30 minutes followed by a median
(range) maintenance dose of 7.5 mg/kg (4.2–15.6) every 12 hours (<14 postnatal days) and
24 hours (≥14 postnatal days). Samples were collected immediately prior to and following
the metronidazole infusion, and approximately 1 to 1.5 hours and 3 to 4 hours post-infusion.
Samples were also collected at 24–25 hours, 48–49 hours, and 72–73 hours for infants <14
postnatal days and at 12–13 hours, 24–25 hours and 36–37 hours post-infusion for infants
≥14 postnatal days.
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Individual metronidazole clearance estimates were from a previously published population
PK model that included body weight and postmenstrual age as covariates.8 The metabolic
ratio was also calculated as described previously by dividing the hydroxyl-metronidazole
steady-state area under the curve from zero to tau (AUC0-τ) by the metronidazole AUC0-τ.8
Following multiple dose administration, the AUC was calculated using the trapezoidal rule
with non-compartmental methods in Phoenix WinNonlin (Certara, Cary, NC). The
metabolite-to-parent concentration ratio was calculated by dividing the nanomolar
concentration of hydroxy-metronidazole by that of metronidazole in each sample. The AUC
and concentration values used to calculate the metabolic ratios and metabolite-to-parent
concentration ratios were converted to μM*h and μM, respectively, to allow for comparison.
A set of descriptive statistics including mean, median, and range was generated for each set
of samples for each infant. The median (range) of medians of the group of infants was then
determined. Simple linear regression was used to examine expected clearance of
metronidazole based on postmenstrual age.
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Genomic deoxyribonucleic acid was isolated from these samples and CYP2A6 genotype
was determined as previously described.9 The assay included the variant alleles CYP2A6*2,
*4, *7, *9, *12, *17, *20, *23–25, *28, *31, and *35, which are prevalent and known to
affect the metabolism of nicotine.10

Results
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The median (range) gestational age at birth of the cohort was 25.4 weeks (23.1–30.9),
median birth weight was 1.2 kg (0.57–1.96), and median postmenstrual age was 30.7 weeks
(23.9–35.3) (Table 1). Of the 14 neonates, 2 were heterozygous for the *17 variant allele
(CYP2A6*1/*17) and 12 had the wild type genotype, CYP2A6*1/*1. Clearance for
metronidazole among the two CYP2A6*1/*17 neonates was 0.044 and 0.031 L/h/kg,
compared to the median (range) value for the CYP2A6*1/*1 neonates of 0.041 L/h/kg
(0.013–0.101). Body-weight normalized clearance for the CYP2A6*1/*17 subjects did not
deviate from the expected clearance predicted by postmenstrual age (Figure 1). The
metabolic ratio of the CYP2A6*1/*17 variant infant fell within the range of the wild type
CYP2A6*1/*1 infants (Table 2). The median hydroxy-metronidazole-to-metronidazole
concentration ratio for the two CYP2A6*1/*17 neonates was 0.106 and 0.236. The median
(range) of hydroxy-metronidazole-to-metronidazole concentration ratios in wild type
CYP2A6*1/*1 infants was 0.093 (0.008–1.066).
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Two CYP2A6*1/*1 infants received phenobarbital, an inducer of CYP2A6, as concomitant
treatment during the course of the study. The clearance values of these infants were 0.018
and 0.043 L/h/kg, which were within the range (0.013–0.101 L/h/kg) of infants who were
not on a CYP2A6 inducer or inhibitor. The two CYP2A6*1/*17 infants did not receive any
known inhibitors or inducers of CYP2A6. A one-way analysis of variance showed that there
was no statistically significant effect of sex or race on clearance in the entire cohort (p >
0.7). Age was found to be a significant covariate in the population PK model previously
published.8

Discussion

Author Manuscript

The results observed in this small cohort of premature infants suggest that there were no
clear trends between CYP2A6*1/*1 and CYP2A6*1/*17 genotype and metronidazole
clearance during the first month of life. The clearance values for the two infants with
CYP2A6*17 variants were within the range of clearance of metronidazole by wild type
infants (*1/*1) of similar postmenstrual age. Additionally, the metabolic ratio and
metabolite-to-parent concentration ratio of the *17 variants also fell within the range of wild
type values. It is important to note that early in life, the hydroxy-metronidazole AUC0-τ
values used in the calculation of the metabolic ratio might not accurately reflect the fraction
of metronidazole converted to hydroxy-metronidazole. This is due to the fact that the plasma
disposition profile is dependent on both the formation and elimination of hydroxymetronidazole. If elimination is rate limiting, the amount of plasma metabolite can appear
high even though only a fraction of metronidazole is converted into hydroxy-metronidazole.
This may be due to the effect of ontogeny and genetic variation on the pathways contributing
to the clearance of hydroxy-metronidazole. In future studies, the fraction of metronidazole
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that has been hydroxylated can be assessed by collecting urine over a dosing interval at
steady state or over 5 half-lives after the first dose. Studies in infants and children examining
cotinine, the major metabolite of nicotine that is exclusively metabolized by CYP2A6, have
demonstrated that genotype becomes a predictor of CYP2A6-mediated cotinine metabolism
only after 2 months of age.11
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In vitro studies implicate CYP2A6 as the primary CYP catalyzing metronidazole 2hydroxylation with six-fold greater activity than the next most active enzyme. Although
heterologously expressed CYP3A4, CYP3A5, and CYP3A7 also form 2-hydroxy
metronidazole, inhibitor studies with human liver microsomes have suggested that CYP3A
enzymes do not contribute significantly to metronidazole 2-hydroxylation at therapeutic
concentrations.5 However, based on the ontogeny of these proteins, it is possible that they
play a more significant role in the metabolism of metronidazole earlier in life due to low
levels of CYP2A6, particularly in preterm neonates. For example, CYP3A7 is uniquely
expressed at high levels in the fetal liver, with expression peaking in the first postnatal week
while CYP3A4 levels increase over the first 6 months of life.12,13 Unlike CYP3A4 and
CYP3A7, CYP2A6 is expressed at extremely low levels in fetal liver and does not reach
adult levels until after the first year of life.14,15 Given that the clearance of metronidazole in
our population of premature infants is lower than values reported in adult populations, it is
possible that the ontogeny of metabolizing enzymes and lower levels of expression early in
life may contribute to the lack of effect of allelic variation on drug metabolism.16
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Another potential explanation for the lack of effect of CYP2A6 genotype on metronidazole
PK observed in our cohort is that the protein product of the CYP2A6*1/*17 variant
(CYP2A6.17) demonstrates substrate specificity. Using nicotine hydroxylation as a
reference for metabolic activity, the CYP2A6*1/*17 infants are expected to be slow
metabolizers and the CYP2A6*1/*1 infants normal metabolizers.17,18 However, the
CYP2A6.17 enzyme catalyzes near normal rates of coumarin 7-hydroxylation.7 If
metronidazole is similar to coumarin as a substrate, there would be no genotype-phenotype
discordance in our cohort since the rate of metronidazole clearance would be expected to be
similar between the two variants. This is not the case for most variants; for example,
CYP2A6*23 has been shown to impair the enzymatic metabolism of both nicotine and
coumarin.7 Further studies are needed to determine the activity of CYP2A6 variants as they
may affect the biotransformation of metronidazole.
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Due to a small sample size, only two genetic variants (CYP2A6*1, CYP2A6*17) were
observed in this study cohort. We did not enroll any children of East Asian descent. Some
variants such as CYP2A6*4 have a frequency ranging from 0–4% in Caucasian and African
Americans to as high as 15–24% in East Asians.19,20 Certain variants are found at
substantially higher frequencies in certain populations, such as the polymorphism
CYP2A6*17 in African Americans and CYP2A6*7 in East Asians.18, 21 While the results
from our study may not be generalizable, they do illustrate the importance of considering the
roles of CYP2A6 allelic variants and ontogeny in the biotransformation of medically
important substrates such as metronidazole.
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Future directions include characterizing the activity of CYP2A6*17 and other variants for
metronidazole 2-hydroxylase activity in vitro. Additionally, the effect of ontogeny on
metronidazole biotransformation could be further examined in groups of older infants to
determine if any genotype-phenotype discordance exists in these populations and, if so,
when it might resolve. These studies will be required to further understand the mechanisms
and timing of any underlying genotype-phenotype discordance.

Conclusions
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In summary, genotype-phenotype relationships for various polymorphic CYP450 enzymes
can be obscured early in life by the interplay between ontogeny and genetic variation. While
genotype-phenotype concordance has been demonstrated as early as 2 weeks after birth for
enzymes such as CYP2D6, other polymorphic enzymes such as CYP2C19 display genotypephenotype discordance persisting into the first few months of life.22,23 While genotypephenotype discordance for CYP2A6 would be expected at 1 month of postnatal life, our
observation in two infants suggests the possibility of an allele specific pattern of
metronidazole metabolism by infants possessing the CYP2A6*17 variant such that this
allele does not have impaired activity toward metronidazole.

Acknowledgments
The Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee
Katherine Y. Berezny, Duke Clinical Research Institute, Durham, NC; Gregory L. Kearns, Arkansas Children’s
Hospital, Little Rock, AR; Ian M. Paul, Penn State College of Medicine, Hershey, PA; Michael J. Smith, University
of Louisville, Louisville, KY; John van den Anker, George Washington University School of Medicine and Health,
Washington, DC; Kelly Wade, Children’s Hospital of Philadelphia, Philadelphia, PA.

Author Manuscript

The Eunice Kennedy Shriver National Institute of Child Health and Human Development: David Siegel, MD,
Perdita Taylor-Zapata, MD, Anne Zajicek, PharmD, Alice Pagan, BBA.
The EMMES Corporation (Data Coordinating Center): Ravinder Anand, PhD, Traci Clemons, PhD, Gina Simone,
BS.
Funding Information

Author Manuscript

D.G. is funded by grant K23HD083465 from the National Institute of Child Health and Human Development
(NICHD) and by the nonprofit Thrasher Research Fund (www.thrasherresearch.org). R.F.T. receives support from
Canadian Institutes of Health Research grant TMH109787, an Endowed Chair in Addiction, and the Campbell
Family Mental Health Research Institute of the Centre for Addiction and Mental Health. D.K.B. Jr. receives support
from the National Institutes of Health (NIH) (award 2K24HD058735-06, National Center for Advancing
Translational Sciences award UL1TR001117, NICHD contract HHSN275201000003I, and National Institute of
Allergy and Infectious Disease [NIAID] contract HHSN272201500006I); he also receives research support from
Cempra Pharmaceuticals (subaward to HHSO100201300009C) for neonatal and pediatric drug development
(www.dcri.duke.edu/research/coi.jsp). M.C.W. receives support for research from the NIH (1R01HD076676-01A1), the National Center for Advancing Translational Sciences of the NIH (UL1TR001117), the
NIAID (HHSN272201500006I and HHSN272201300017I), the NICHD (HHSN275201000003I), the Food and
Drug Administration (1U01FD004858-01), the Biomedical Advanced Research and Development Authority
(HHSO100201300009C), the nonprofit Thrasher Research Fund (www.thrasherresearch.org), and from industry for
drug development in adults and children (www.dcri.duke.edu/research/coi.jsp). The funders had no role in study
design, data collection and interpretation, or the decision to submit the work for publication. The content is solely
the responsibility of the authors and does not necessarily represent the official views of the NIH. The remaining
authors have no relevant disclosures to report.

J Clin Pharmacol. Author manuscript; available in PMC 2018 February 01.

Wang et al.

Page 6

Author Manuscript

References

Author Manuscript
Author Manuscript
Author Manuscript

1. Brook I. Bacteremia due to anaerobic bacteria in newborns. J Perinatol. 1990; 10(4):351–356.
[PubMed: 2277280]
2. Thompson AM, Bizzarro MJ. Necrotizing enterocolitis in newborns: pathogenesis, prevention and
management. Drugs. 2008; 68(9):1227–1238. [PubMed: 18547133]
3. O’Keefe JP, Troc KA, Thompson KD. Activity of metronidazole and its hydroxy and acid
metabolites against clinical isolates of anaerobic bacteria. Antimicrob Agents Chemother. 1982;
22(3):426–430. [PubMed: 7137984]
4. Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the
nitroimidazole antimicrobials. Clin Pharmacokinet. 1999; 36(5):353–373. [PubMed: 10384859]
5. Pearce RE, Cohen-Wolkowiez M, Sampson MR, Kearns GL. The role of human cytochrome P450
enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km)
catalyst. Drug Metab Dispos. 2013; 41(9):1686–1694. [PubMed: 23813797]
6. Hines RN. The ontogeny of drug metabolism enzymes and implications for adverse drug events.
Pharmacol Ther. 2008; 118(2):250–267. [PubMed: 18406467]
7. Ho MK, Mwenifumbo JC, Zhao B, Gillam EM, Tyndale RF. A novel CYP2A6 allele, CYP2A6*23,
impairs enzyme function in vitro and in vivo and decreases smoking in a population of BlackAfrican descent. Pharmacogenet Genomics. 2008; 18(1):67–75. [PubMed: 18216723]
8. Cohen-Wolkowiez M, Sampson M, Bloom BT, et al. Determining population and developmental
pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature
infants. Pediatr Infect Dis J. 2013; 32(9):956–961. [PubMed: 23587979]
9. Wassenaar CA, Zhou Q, Tyndale RF. CYP2A6 genotyping methods and strategies using real-time
and end point PCR platforms. Pharmacogenomics. 2016; 17(2):147–62. [PubMed: 26670214]
10. The Human Cytochrome P450 (CYP) Allele Nomenclature Database: CYP2A6 Allele
Nomenclature. Karolinska Institute; website. http://www.cypalleles.ki.se/cyp2a6.htm. Updated
January 21, 2014. Accessed May 20, 2016
11. Dempsey DA, Sambol NC, Jacob P 3rd, et al. CYP2A6 genotype but not age determines cotinine
half-life in infants and children. Clin Pharmacol Ther. 2013; 94(3):400–406. [PubMed: 23714690]
12. Yang H-YL, Lee QP, Rettie AR, Juchau MR. Functional cytochrome P450A3 isoforms in human
embryonic tissues: expression during organogenesis. Mol Pharmacol. 1994; 46(5):922–928.
[PubMed: 7969081]
13. Stevens JC, Hines RN, Gu C, et al. Developmental expression of the major human hepatic CYP3A
enzymes. J Pharmacol Exp Ther. 2003; 307(2):573–582. [PubMed: 12975492]
14. Tateishi T, Nakamura H, Asoh M, et al. A comparison of hepatic cytochrome P450 protein
expression between infancy and post-infancy. Life Sci. 1997; 61(26):2567–2574. [PubMed:
9416779]
15. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human
liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens, and toxic
chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp
Ther. 1994; 270(1):414–423. [PubMed: 8035341]
16. Sprandel KA, Drusano GL, Hecht DW, Rotschafer JC, Danziger LH, Rodvold KA. Population
pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous
metronidazole. Diagn Microbiol Infect Dis. 2006; 55(4):303–309. [PubMed: 16887471]
17. Ho MK, Mwenifumbo JC, Al Koudsi N, et al. Association of nicotine metabolite ratio and
CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin
Pharmacol Ther. 2009; 85(6):635–643. [PubMed: 19279561]
18. Fukami T, Nakajima M, Yoshida R, et al. A novel polymorphism of human CYP2A6 gene
CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro
and in vivo. Clin Pharmacol Ther. 2004; 76(6):519–527. [PubMed: 15592323]
19. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6 and
association of genetically slow nicotine metabolism and smoking in adult Caucasians.
Pharmacogenetics. 2004; 14(9):615–626. [PubMed: 15475735]

J Clin Pharmacol. Author manuscript; available in PMC 2018 February 01.

Wang et al.

Page 7

Author Manuscript

20. Minematsu N, Nakamura H, Furuuchi M, et al. Limitation of cigarette consumption by
CYP2A6*4, *7, and *9 polymorphisms. Eur Respir J. 2006; 27(2):289–292. [PubMed: 16452582]
21. Nakajima M, Fukami T, Yamanaka H, et al. Comprehensive evaluation of variability in nicotine
metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther.
2006; 80(3):282–297. [PubMed: 16952495]
22. Ward RM, Tammara B, Sullivan SE, et al. Single-dose, multiple-dose, and population
pharmakokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of
gastroesophageal reflux disease (GERD). Eur J Clin Pharmacol. 2010; 66(6):555–561. [PubMed:
20306184]
23. Leeder JS, Kearns GL. Interpreting pharmacogenetic data in the developing neonate: the challenge
of hitting a moving target. Clin Pharmacol Ther. 2012; 92(4):434–436. [PubMed: 22948896]

Author Manuscript
Author Manuscript
Author Manuscript
J Clin Pharmacol. Author manuscript; available in PMC 2018 February 01.

Wang et al.

Page 8

Author Manuscript
Author Manuscript
Author Manuscript

Figure 1.

Plasma clearance of metronidazole (L/h/kg) versus postmenstrual age (weeks). Individuals
with variant genotype (CYP2A6*1/*17) are shown as triangles and wild type genotype
(CYP2A6*1/*1) as circles.
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Demographics Stratified by CYP2A6 Genotype
CYP2A6 *1/*1
n=12

CYP2A6 *1/*17
n=2

25.7 (23.1–30.9)

25.2 (25.1–25.3)

30 (1–66)

20 (11–29)

Postmenstrual age, weeks

31.6 (23.9–35.3)

28.1 (26.7–29.4)

Birth weight, kg

1.33 (0.57–1.96)

0.83 (0.69–0.96)

Race

6 (50) White/Caucasian
4 (33) Black/African American
2 (17) other

2 (100) Black/African American

Sex

8 (67) female

2 (100) female

Gestational age, weeks
Postnatal age, days

Median (range) is provided for continuous data and n (%) for categorical data.
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1.64

30.28
23.85
29.57
33.28
32.00
34.86
35.29
33.57
31.15
33.86
26.71
29.43

*1/ *1

*1/ *1

*1/ *1

*1/ *1

*1/ *1

*1/ *1

*1/ *1

*1/ *1

*1/ *1

*1/ *1

*1/ *17

*1/ *17

Metabolic ratio =

a

AUC, area under the curve; NE, not estimated.

1.35

25.14

*1/ *1

0.96

0.69

1.76

1.96

1.56

0.93

1.09

1.34

0.57

1.31

0.75

0.61

24.71

*1/ *1

Body Weight
(kg)

Postmenstrual Age
(weeks)

CYP2A6 Genotype

0.03

0.04

0.04

0.04

0.04

0.08

0.04

0.04

0.10

0.02

0.02

0.06

0.01

0.02

Clearance
(L/hr/kg)

101.52

NE

106.87

NE

NE

154.96

58.78

64.12

363.34

128.24

NE

74.81

26.72

443.49

Hydroxy-metronidazole AUC0-τ
(μM*h)

1051.71

858.90

1051.71

NE

NE

584.28

946.54

870.58

385.63

1343.85

2161.85

683.61

2325.45

2091.73

Metronidazole AUC0-τ
(μM*h)

0.10

—

0.10

—

—

0.27

0.06

0.07

0.94

0.10

—

0.11

0.01

0.21

Metabolic Ratioa

Metronidazole Clearance, Hydroxyl-Metronidazole Area Under the Curve, Metronidazole Area Under the Curve, and Metabolic Ratio for Each Infant
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